This trial is terminated!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Treatment-Resistant Depression
and you are
between 18 and 65
years old
Phase
-
This is an observational trial.
You are contributing to medical knowledge about your condition.
Show me locations

The purpose

This is an ancillary study to a clinical trial that is being conducted at Massachusetts General Hospital. Investigators at MGH are conducting a clinical trial to test the efficacy of ziprasidone together with escitalopram for treatment-resistant depression (NCT00633399). This observational study will involve magnetic resonance scans to examine brain chemistry (neurotransmitter levels), brain activity, and functional connections between brain regions before and after participating in the trial. The neurotransmitters of interest are glutamate, glutamine, and GABA. Comparisons will be made between individuals who receive ziprasidone and individuals who receive an inactive placebo. Differences between participants who respond to standard antidepressants and those who require additional medication will also be examined. All participants will have a baseline magnetic resonance scan before starting medication. The second scan will be after 8 weeks of escitalopram treatment for those who respond or following 8 weeks of escitalopram plus ziaprasidone or placebo (16 weeks after starting) for those who do not respond to escitalopram alone. Participants will complete standard rating scales for depression at each visit.
Tris trial is registered with FDA with number: NCT01598324. The sponsor of the trial is Mclean Hospital and it is looking for 1 volunteers for the current phase.
Official trial title:
Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder